Browse > Article
http://dx.doi.org/10.3339/jkspn.2014.18.1.18

Effects of Age and Sex on the Pharmacokinetics of Tacrolimus during Pediatric Kidney Transplantation: A Single Center Study  

Choe, Jae Young (Department of Pediatrics, Kyungpook National University School)
Jang, Kyung Mi (Department of Pediatrics, Kyungpook National University School)
Hwang, Young Ju (Department of Pediatrics, Kyungpook National University School)
Choi, Bong Seok (Department of Pediatrics, Kyungpook National University School)
Park, Jong Kwang (Kyungpook National University School of Medicine Clinical Trial Center)
Yoon, Young Ran (Kyungpook National University School of Medicine Clinical Trial Center)
Kim, Chan Duck (Department of Internal Medicine, Kyungpook National University School)
Cho, Min Hyun (Department of Pediatrics, Kyungpook National University School)
Publication Information
Childhood Kidney Diseases / v.18, no.1, 2014 , pp. 18-23 More about this Journal
Abstract
Purpose: The pharmacokinetics of tacrolimus, one of the most widely used immunosuppressive drugs, are known to vary by sex, age, and ethnicity during pediatric transplantation. This study assessed the pharmacokinetic characteristics and associated factors of tacrolimus in Korean children receiving a kidney transplant. Methods: We retrospectively reviewed the pharmacokinetic data (therapeutic dose, trough level, clearance, and half-life) of 9 children who were given tacrolimus as one of their initial immunosuppressive drugs after kidney transplantation. In addition, we compared the findings to data from 10 adult kidney transplant recipients. Results: The mean age of our pediatric patients was 13.9 years, and the maleto- female ratio was 4:5. The mean dose of tacrolimus was $0.19{\pm}0.14$ mg/kg/day. The mean dose of tacrolimus for males was $0.23{\pm}0.12$ mg/kg/day, which was significantly higher than the dose for females ($0.16{\pm}0.14$ mg/kg/day). The trough level was not significantly different between both groups. The clearance rate of tacrolimus for males was also significantly higher than females. Although the dosage of tacrolimus for patients over the age of 12 years was lower ($0.18{\pm}0.13$ vs. $0.21{\pm}0.16$ mg/kg/day) and the trough level was higher ($8.2{\pm}4.5$ vs. $7.2{\pm}4.2$ mg/mL) than that for patients under the age of 12 years, there was no significant difference between them. However, there were significant differences between children and adults in dose, clearance, and half-life of tacrolimus. Conclusion: Out study suggests that the pharmacokinetics of tacrolimus tends to vary with sex and age. Therefore, large-scale prospective studies are required to verify the proper therapeutic dosage of tacrolimus in Korean children.
Keywords
Tacrolimus; Kidney transplantation; Pharmacokinetics; Children;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005;9:162-9.   DOI   ScienceOn
2 Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother 2008;9:635-43.   DOI   ScienceOn
3 Ellis D, Shapiro R, Jordan ML, Scantlebury VP, Gilboa N, Hopp L, et al. Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 1994;8:193-200.   DOI   ScienceOn
4 Dunn TB, Asolati M, Holman DM, Raofi V, Jovanovic B, Pollak R, et al. Long-term outcomes of a prospective trial of steroid withdrawal after kidney transplantation. Surgery 1999;125: 155-9.   DOI   ScienceOn
5 Sarwal MM, Vidhun J, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003;76:1331-9.   DOI   ScienceOn
6 Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10:1366-80.
7 Matas AJ, Smith JM, Skeans MA. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant 2013;13(suppl 1):11-46.
8 Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003;63:1247-97.   DOI   ScienceOn
9 Halloran PF. Molecular mechanisms of new immunosuppres-sants. Clin Transplant 1996;10:118-23.
10 Kang HK. Allograft immune reaction of kidney transplantation. J Korean Soc Pediatr Nephrol 2008;12:133-42.   DOI   ScienceOn
11 Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-14.
12 Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. A phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-8.
13 Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lom-bardozzi-Lane S, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999;67:299-303.   DOI
14 Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006;112:184-98.   DOI   ScienceOn
15 Naesens M, Salvatierra O, Li L, Kambham N, Concepcion W, Sarwal M. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation 2008;85:1139-45.   DOI   ScienceOn
16 Felipe CR, Silva Jr HT, Machado PG, Garcia R, da Silva Moreira SR, Pestana JO. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant 2002;16:262-72.   DOI   ScienceOn
17 Mancinelli LM, Frassetto L, Floren LC. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther 2001;69:24-31.   DOI   ScienceOn
18 Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000;26: 601-5.   DOI
19 Kim JS. Tacrolimus versus cyclosporine immunosuppression in pediatric renal transplantation: Pharmacokinetic consideration. Korean J of Pediatr 2005;48:476-80.
20 Delaloye JR, Kassir N, Lapeyraque AL, Alvarez F, Lallier M, Beaunoyer M, et al. Limited sampling strategies for monitoring Tacrolimus in pediatric liver transplant recipients. Ther Drug Monit 2011;33:380-6.   DOI   ScienceOn
21 Zhao W, Fakhoury M, Baudouin V, Maisin A, Deschênes G, Jacqz-Aigrain E. Limited sampling strategy for estimating individual exposure of Tacrolimus in pediatric kidney transplant patients. Ther Drug Monit 2011;33:681-7.   DOI   ScienceOn
22 ShishidoS, Asanuma H, Tajima E, Honda M, Nakai H. Pharma-cokinetics of Tacrolimus in pediatric renal transplant recipients. Transplant Proc 2001;33:1066-8.   DOI   ScienceOn
23 Filler G, Grygas R, Mai I, Stolpe HJ, Greiner C, Bauer S. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997;12: 1668-71.   DOI   ScienceOn
24 McDiarmid SV, Colonna JO 2nd, Shaked A, Vargas J, Ament ME, Busuttil RW. Differences in oral FK506 dose requirements between adults and pediatric liver transplant patients. Transplantation 1993;55:1328-32.   DOI
25 ZhaoW, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit 2010;32:688-99.   DOI   ScienceOn
26 Wallemacq PE, Furlan V, Möller A, Schäfer A, Stadler P, Firdaous I, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Metab Pharmacokinet 1998;23:367-70.   DOI   ScienceOn
27 Cherala G, Munar MY, Naher A, Al-Uzri A. Tacrolimus pharmacokinetics in Hispanic children after kidney transplantation. Transplant Proc 2011;43:3708-12.   DOI   ScienceOn